16 November 2015 - The manufacturer presented no relevant data for the assessment of the added benefit of insulin degludec/liraglutide versus the appropriate comparator therapy.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/insulin-degludec-plus-liraglutide-again-no-hint-of-added-benefit-in-type-2-diabetes.7055.html